ABL001, also named asciminib, targets the myristoyl pocket of ABL1 in an allosteric manner and simulates the natural N-terminal myristoyl peptide of ABL1, which restores the self-inhibitory conformation of tyrosine kinase and realizes the treatment effect of CML (Jones et al., 2020). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.